ALLOPAX- levocetirizine dihydrochloride 5%, loratadine 5% kit

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

LORATADINE (UNII: 7AJO3BO7QN) (LORATADINE - UNII:7AJO3BO7QN)

Available from:

PharmaGenetico LLC

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Each Allo•PAX provides 3 grams of Levocetirizine dihydrochloride, 3 grams Loratadine USP, and 54 grams of Base. The resulting mixture is intended for transdermal use.

Authorization status:

unapproved drug other

Summary of Product characteristics

ALLOPAX- LEVOCETIRIZINE DIHYDROCHLORIDE 5%, LORATADINE 5%
PHARMAGENETICO LLC
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
ALLOPAX
Each Allo•PAX provides 3 grams of Levocetirizine dihydrochloride, 3
grams Loratadine USP, and 54
grams of Base. The resulting mixture is intended for transdermal use.
For Prescription Use Only
Distributed by:
PharmaGenetico LLC
San Antonio, TX 78257
ALLOPAX
levocetirizine dihydrochloride 5%, loratadine 5% kit
PRODUCT INFORMATION
PRODUCT T YPE
HUMAN PRESCRIPTION DRUG
ITE M CODE (SOURCE )
NDC:6 9 8 17-0 20 1
PACKAG ING
#
ITEM CODE
PACKAGE DESCRIPTION
MARKETING START DATE
MARKETING END DATE
1
NDC:6 9 8 17-0 20 1-1
1 in 1 BOX; Type 0 : No t a Co mbinatio n Pro duct
0 6 /30 /20 15
11/23/20 16
QUANTITY OF PARTS
PART #
PACKAGE QUANTITY
TOTAL PRODUCT QUANTITY
PA RT 1
1 BOTTLE, PLASTIC
3 g in 3
PA RT 2
1 BOTTLE, PLASTIC
3 g in 3
PA RT 3
1 JAR
54 g in 54
PART 1 OF 3
LORATADINE
loratadine powder, for suspension
PRODUCT INFORMATION
ROUTE OF ADMINISTRATION
TRANSDERMAL
ACTIVE INGREDIENT/ACTIVE MOIETY
INGREDIENT NAME
BASIS OF STRENGTH
STRE NG TH
LO RATADINE (UNII: 7AJO3BO7QN) (LORATADINE - UNII:7AJO3BO7QN)
LORATADINE
3 g in 3 g
PACKAG ING
# ITEM CODE
PACKAGE DESCRIPTION
MARKETING START DATE
MARKETING END DATE
1
3 g in 1 BOTTLE, PLASTIC; Type 0 : No t a Co mbinatio n Pro duct
MARKETING INFORMATION
MARKE TING CATE GORY
APPLICATION NUMBE R OR MONOGRAPH CITATION
MARKE TING START DATE
MARKE TING END DATE
unappro ved drug o ther
PART 2 OF 3
LEVOCETIRIZINE DIHYDROCHLORIDE
levocetirizine dihydrochloride powder, for suspension
PRODUCT INFORMATION
ROUTE OF ADMINISTRATION
TRANSDERMAL
ACTIVE INGREDIENT/ACTIVE MOIETY
INGREDIENT NAME
BASIS OF STRENGTH
STRE NG TH
LEVO CETIRIZINE DIHYDRO CHLO RIDE (UNII: SOD6 A38 AGA) (LEVOCETIRIZINE
-
UNII:6 U5EA9 RT2O)
LEVOCETIRIZINE
DIHYDROCHLORIDE
3 g in 3 g
PACKAG ING
# ITEM CODE
PACKAGE DESCRIPTION
MARKETING START DATE
MARKET